Perrigo Has Approval For Copy Of OTC Voltaren Arthritis Relief Before GSK Launches The Brand
Executive Summary
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.
You may also be interested in...
OTC Decisions August-October: More Providers Enter Diclofenac, Lansoprazole, Loratadine Markets
CDER’s August-September OTC application approvals are highlighted by Arbor Pharmaceuticals’ ivermectin 0.5% lice treatment. Orange Book changes also include four firms’ approvals for labeling to market generic equivalents of Voltaren Arthritis Relief launched as an OTC switch since earlier in 2020.
Dr Reddy’s Enters OTC Eyecare Space
Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.
Perrigo’s Pending OTC Launches Promising But Pandemic Precludes Pumping Guidance
A diclofenac topical analgesic is first, likely followed by a line extension for its Prevacid 24HR PPI brand. Perrigo also plans to introduce natural-based products that “leverage our expertise in Europe."
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: